Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Geron Corp (NASDAQ:GERN)

Thursday’s trading has closed, but GERN is being traded in the after-hours session. After-Hours quote »
Delayed Data
As of 4:00pm ET
 -0.04 / -1.55%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Geron Corp. discovers and develops therapeutic products for cancer. It is a clinical stage biopharmaceutical company developing a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company's imetelstat, their sole product candidate, is a potent and specific inhibitor of telomerase. Based on clinical data, they may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or MF, which includes patients with primary MF, post-essential thrombocythemia MF, myelodysplastic syndromes, acute myelogenous leukemia. Geron was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.

Contact Information

Geron Corp.
149 Commonwealth Drive
Menlo Park California 94025
P:(650) 473-7700
Investor Relations:
(650) 473-7765



Individual stakeholders6.20%
Mutual fund holders32.37%
Other institutional15.93%

Top Executives

John A. ScarlettPresident, Chief Executive Officer & Director
Olivia K. BloomChief Financial Officer, Treasurer & Executive VP
Stephen N. RosenfieldSecretary, Executive VP & General Counsel
Melissa A. Kelly BehrsExecutive Vice President-Business Development
Andrew J. GrethleinExecutive VP-Development & Technical Operations